Health Care • Biotechnology: Pharmaceutical Preparations
$0.95 ▼ -0.02
(-2.30%)
MKT CAP: $607.9M • VOL: 32.35M
52W L $1 52W H $2
ROARABLE / RQD
D- • 37/100
PIOTROSKI
3 / 9
GERN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $237.0K |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$68.6M | -$173.7M | -$193.9M |
| Operating Margin % | — | — | -80.0% |
| Net Income (GAAP) | -$83.5M | -$174.6M | -$184.1M |
| EBITDA (Normalized) | — | -$173.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$111.0M | -$218.6M | -$167.7M |
| Capital Expenditures (CapEx) | — | $680.0K | — |
| Free Cash Flow (FCF) | -$111.0M | -$219.3M | -$167.7M |
| FCF Margin % | — | — | -80.0% |
| Return on Invested Capital (ROIC %) | -20.2% | -42.9% | — |
| Cash & Short-Term Equivalents | $77.6M | $79.0M | — |
| Total Debt (Short + Long Term) | $119.5M | $118.5M | — |
| Total Stockholders' Equity | $225.9M | $280.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR GERN.